Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.

Srisurapanont M, Suttajit S, Likhitsathian S, Suradom C, Maneeton B

International journal of psychiatry in medicine31 Jan 2026

PMID41618880DOI10.1177/00912174261422822PepBankPUB-41618880

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with severe mental illness and cardiometabolic risk, low-certainty pooled GLP-1 receptor agonist evidence reported 6.17 kg weight reduction versus placebo/usual care, with substantial heterogeneity (I²91.8%).
In plain wordsIn severe mental illness, low-certainty pooled GLP-1 evidence reported weight reduction versus placebo/usual care, with substantial heterogeneity.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight reduction
6.17 kg
versus placebo/usual care; 9 trials
Source sentences
Summary
Compared with placebo/usual care, GLP- 1RAs significantly reduced weight (MD = 6.17 kg, 95% CI=9.10 to_3.25, I² = 91.8%, 9 trials) and HbA1c (MD = 0.31%, 95% CI: 0.40 to 0.22, I² = 51.3%, 8 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4161888001
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with severe mental illness and cardiometabolic risk, low-certainty pooled GLP-1 receptor agonist evidence reported 6.17 kg weight reduction versus placebo/usual care, with substantial heterogeneity (I²91.8%).
In plain wordsIn severe mental illness, low-certainty pooled GLP-1 evidence reported weight reduction versus placebo/usual care, with substantial heterogeneity.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight reduction
6.17 kg
versus placebo/usual care; 9 trials
Source sentences
Summary
Compared with placebo/usual care, GLP- 1RAs significantly reduced weight (MD = 6.17 kg, 95% CI=9.10 to_3.25, I² = 91.8%, 9 trials) and HbA1c (MD = 0.31%, 95% CI: 0.40 to 0.22, I² = 51.3%, 8 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4161888002
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with severe mental illness and cardiometabolic risk, low-certainty pooled GLP-1 receptor agonist evidence reported 0.31% HbA1c reduction versus placebo/usual care (I²51.3%).
In plain wordsLow-certainty pooled GLP-1 receptor agonist evidence reported 0.31% HbA1c reduction versus placebo or usual care in people with severe mental illness.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c reduction
0.31%
versus placebo/usual care; 8 trials
Source sentences
Summary
Compared with placebo/usual care, GLP- 1RAs significantly reduced weight (MD = 6.17 kg, 95% CI=9.10 to_3.25, I² = 91.8%, 9 trials) and HbA1c (MD = 0.31%, 95% CI: 0.40 to 0.22, I² = 51.3%, 8 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4161888003
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with severe mental illness and cardiometabolic risk, low-certainty pooled GLP-1 receptor agonist evidence reported 0.31% HbA1c reduction versus placebo/usual care (I²51.3%).
In plain wordsLow-certainty pooled GLP-1 receptor agonist evidence reported 0.31% HbA1c reduction versus placebo or usual care in people with severe mental illness.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c reduction
0.31%
versus placebo/usual care; 8 trials
Source sentences
Summary
Compared with placebo/usual care, GLP- 1RAs significantly reduced weight (MD = 6.17 kg, 95% CI=9.10 to_3.25, I² = 91.8%, 9 trials) and HbA1c (MD = 0.31%, 95% CI: 0.40 to 0.22, I² = 51.3%, 8 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4161888004
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with severe mental illness, pooled GLP-1 receptor agonists including liraglutide and semaglutide did not differ significantly from placebo/usual care in all-cause dropouts; acceptability evidence had moderate certainty.
In plain wordsIn people with severe mental illness, all-cause dropouts did not differ significantly between pooled GLP-1 receptor agonists and placebo or usual care.
Peptide
Liraglutide
Outcome
No significant changeAll-cause dropouts
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
Risk ratio
0.98
all-cause dropouts; 10 trials
Source sentences
Summary
All-cause dropouts did not differ significantly between groups (RR = 0.98, 95% CI: 0.71 to 1.35, I² = 28.5%, 10 trials), nor did adverse effect dropouts (RR = 0.99, 95% CI: 0.35 to 2.77, I² = 31.6%, 5 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Moderate certainty evidence also supports their acceptability.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4161888005
06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with severe mental illness, pooled GLP-1 receptor agonists including liraglutide and semaglutide did not differ significantly from placebo/usual care in all-cause dropouts; acceptability evidence had moderate certainty.
In plain wordsIn people with severe mental illness, all-cause dropouts did not differ significantly between pooled GLP-1 receptor agonists and placebo or usual care.
Peptide
Semaglutide
Outcome
No significant changeAll-cause dropouts
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
Risk ratio
0.98
all-cause dropouts; 10 trials
Source sentences
Summary
All-cause dropouts did not differ significantly between groups (RR = 0.98, 95% CI: 0.71 to 1.35, I² = 28.5%, 10 trials), nor did adverse effect dropouts (RR = 0.99, 95% CI: 0.35 to 2.77, I² = 31.6%, 5 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Moderate certainty evidence also supports their acceptability.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4161888006
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with severe mental illness, pooled GLP-1 receptor agonists including liraglutide and semaglutide did not differ significantly from placebo/usual care in adverse-effect dropouts; tolerability evidence had low certainty.
In plain wordsIn people with severe mental illness, adverse-effect dropouts did not differ significantly between pooled GLP-1 receptor agonists and placebo or usual care.
Peptide
Liraglutide
Outcome
No significant changeAdverse-effect dropouts
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
Risk ratio
0.99
adverse-effect dropouts; 5 trials
Source sentences
Summary
All-cause dropouts did not differ significantly between groups (RR = 0.98, 95% CI: 0.71 to 1.35, I² = 28.5%, 10 trials), nor did adverse effect dropouts (RR = 0.99, 95% CI: 0.35 to 2.77, I² = 31.6%, 5 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4161888007
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with severe mental illness, pooled GLP-1 receptor agonists including liraglutide and semaglutide did not differ significantly from placebo/usual care in adverse-effect dropouts; tolerability evidence had low certainty.
In plain wordsIn people with severe mental illness, adverse-effect dropouts did not differ significantly between pooled GLP-1 receptor agonists and placebo or usual care.
Peptide
Semaglutide
Outcome
No significant changeAdverse-effect dropouts
Study
n: not reported in source
Comparator
Placebo/usual care
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
Risk ratio
0.99
adverse-effect dropouts; 5 trials
Source sentences
Summary
All-cause dropouts did not differ significantly between groups (RR = 0.98, 95% CI: 0.71 to 1.35, I² = 28.5%, 10 trials), nor did adverse effect dropouts (RR = 0.99, 95% CI: 0.35 to 2.77, I² = 31.6%, 5 trials).
4 context sentences(design, population, supporting numbers)
Summary · context
Low certainty evidence supports the tolerability and efficacy of GLP-1RAs for weight and HbA1c reduction.
Summary · context
Mean differences (MDs) and risk ratios (RRs) were estimated using a frequentist random-effects model.ResultsIncluded were 10 RCTs (N = 665) of exenatide, liraglutide, and semaglutide.
Summary · context
Participants were those with schizophrenia, schizophrenia-spectrum disorders, or bipolar disorder with cardiometabolic risk.
Summary · context
Primary outcomes were weight reduction, glycated hemoglobin (HbA1c) reduction, all-cause dropouts, and adverse effect dropouts.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4161888008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.